Richard J Sylvester

Summary

Affiliation: EORTC Data Center
Country: Belgium

Publications

  1. ncbi request reprint Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials
    Richard J Sylvester
    European Organisation for Research and Treatment of Cancer Data Center, Brussels, Belgium
    J Urol 168:1964-70. 2002
  2. ncbi request reprint The side effects of Bacillus Calmette-Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial
    Richard J Sylvester
    European Organisation for Research and Treatment of Cancer Data Center, 83 avenue E Mounier, Bte 11, 1200, Brussels, Belgium
    Eur Urol 44:423-8. 2003
  3. ncbi request reprint Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials
    Richard J Sylvester
    European Organization for the Research and Treatment of Cancer Data Center, Brussels, Belgium
    J Urol 174:86-91; discussion 91-2. 2005
  4. ncbi request reprint High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder
    Richard J Sylvester
    European Organization for Research and Treatment of Cancer Data Center, Brussels, Belgium
    Urology 66:90-107. 2005
  5. ncbi request reprint Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials
    Richard J Sylvester
    EORTC Data Center, Brussels, Belgium
    Eur Urol 49:466-5; discussion 475-7. 2006
  6. pmc Combining a molecular profile with a clinical and pathological profile: biostatistical considerations
    Richard J Sylvester
    EORTC Headquarters, 83 avenue E Mounier, Brussels, Belgium
    Scand J Urol Nephrol Suppl . 2008
  7. pmc The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials
    Richard J Sylvester
    EORTC Data Center, Brussels, Belgium
    Eur Urol 53:709-19. 2008
  8. ncbi request reprint Editorial comment on: prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials
    Richard J Sylvester
    EORTC Data Center, Brussels, Belgium
    Eur Urol 53:1002. 2008
  9. ncbi request reprint Natural history, recurrence, and progression in superficial bladder cancer
    Richard J Sylvester
    European Organisation for Research and Treatment of Cancer Data Center, Brussels, Belgium
    ScientificWorldJournal 6:2617-25. 2006
  10. pmc Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk
    Richard J Sylvester
    EORTC Headquarters, Brussels, Belgium
    Eur Urol 57:766-73. 2010

Collaborators

Detail Information

Publications19

  1. ncbi request reprint Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials
    Richard J Sylvester
    European Organisation for Research and Treatment of Cancer Data Center, Brussels, Belgium
    J Urol 168:1964-70. 2002
    ..We determine if intravesical bacillus Calmette-Guerin (BCG) reduces the risk of progression after transurethral resection to stage T2 disease or higher in patients with superficial (stage Ta, T1 or carcinoma in situ) bladder cancer...
  2. ncbi request reprint The side effects of Bacillus Calmette-Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial
    Richard J Sylvester
    European Organisation for Research and Treatment of Cancer Data Center, 83 avenue E Mounier, Bte 11, 1200, Brussels, Belgium
    Eur Urol 44:423-8. 2003
    ....
  3. ncbi request reprint Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials
    Richard J Sylvester
    European Organization for the Research and Treatment of Cancer Data Center, Brussels, Belgium
    J Urol 174:86-91; discussion 91-2. 2005
    ..We determined the short-term and long-term efficacy of bacillus Calmette-Guerin (BCG) and chemotherapy in the treatment of patients with carcinoma in situ (CIS)...
  4. ncbi request reprint High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder
    Richard J Sylvester
    European Organization for Research and Treatment of Cancer Data Center, Brussels, Belgium
    Urology 66:90-107. 2005
    ..These evidence-based guidelines have been developed to aid clinicians in the diagnosis and treatment of patients with high-grade Ta urothelial carcinoma and CIS...
  5. ncbi request reprint Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials
    Richard J Sylvester
    EORTC Data Center, Brussels, Belgium
    Eur Urol 49:466-5; discussion 475-7. 2006
    ..To provide tables that allow urologists to easily calculate a superficial bladder cancer patient's short- and long-term risks of recurrence and progression after transurethral resection...
  6. pmc Combining a molecular profile with a clinical and pathological profile: biostatistical considerations
    Richard J Sylvester
    EORTC Headquarters, 83 avenue E Mounier, Brussels, Belgium
    Scand J Urol Nephrol Suppl . 2008
    ..It is important for investigators to be aware of these pitfalls in order to develop statistically valid classifiers that will truly improve our ability to predict a patient's risk of progression...
  7. pmc The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials
    Richard J Sylvester
    EORTC Data Center, Brussels, Belgium
    Eur Urol 53:709-19. 2008
    ..The objective is to determine the effect of schedule and duration of intravesical chemotherapy on recurrence in patients with stage Ta T1 bladder cancer...
  8. ncbi request reprint Editorial comment on: prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials
    Richard J Sylvester
    EORTC Data Center, Brussels, Belgium
    Eur Urol 53:1002. 2008
  9. ncbi request reprint Natural history, recurrence, and progression in superficial bladder cancer
    Richard J Sylvester
    European Organisation for Research and Treatment of Cancer Data Center, Brussels, Belgium
    ScientificWorldJournal 6:2617-25. 2006
    ..Assessment of a patient's prognostic factors and his or her risk of recurrence and progression is a prerequisite for determining the most appropriate treatment and frequency of follow-up for a given patient...
  10. pmc Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk
    Richard J Sylvester
    EORTC Headquarters, Brussels, Belgium
    Eur Urol 57:766-73. 2010
    ....
  11. doi request reprint Bacillus Calmette-Guérin treatment of non-muscle invasive bladder cancer
    Richard J Sylvester
    Department of Biostatistics, European Organization for Research and Treatment of Cancer Headquarters, Brussels, Belgium
    Int J Urol 18:113-20. 2011
    ..Further research is urgently needed to identify markers associated with BCG failure and to develop effective alternatives to cystectomy in patients failing BCG...
  12. ncbi request reprint A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials
    Richard J Sylvester
    European Organization for the Research and Treatment of Cancer Data Center, Brussels, the Universitair Ziekenhuis Gent, Gent, Belgium
    J Urol 171:2186-90, quiz 2435. 2004
    ..We determined if 1 immediate instillation of chemotherapy after transurethral resection (TUR) decreases the risk of recurrence in patients with stage Ta T1 single and multiple bladder cancer overall and separately...
  13. doi request reprint EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin
    Samantha Cambier
    EORTC Headquarters, Brussels, Belgium
    Eur Urol 69:60-9. 2016
    ..There are no prognostic factor publications on stage Ta-T1 non-muscle-invasive bladder cancer (NMIBC) treated with 1-3 yr of maintenance bacillus Calmette-Guérin (BCG)...
  14. ncbi request reprint Intravesical chemotherapy in non-muscle-invasive bladder cancer: what schedule and duration of treatment?
    Richard J Sylvester
    Eur Urol 52:951-3; discussion 953-4. 2007
  15. ncbi request reprint The use of intravesical chemotherapy and possibilities for improving its efficacy
    Richard J Sylvester
    Eur Urol 50:233. 2006
  16. ncbi request reprint Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906)
    Theo M de Reijke
    Academic Medical Center, Amsterdam, The Netherlands
    J Urol 173:405-9. 2005
    ..We compared the efficacy and side effects of intravesical instillations of bacillus Calmette-Guerin (BCG) and epirubicin in patients with carcinoma in situ (CIS) of the bladder...
  17. ncbi request reprint Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial
    Adrian P M van der Meijden
    Department of Urology, Jeroen Bosch Hospital, P O Box 90153, 5200 ME, s Hertogenbosch, The Netherlands
    Eur Urol 44:429-34. 2003
    ....
  18. ncbi request reprint Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies
    Maurizio Brausi
    Institute Sant Agostino, Estense, Modena, Italy
    Eur Urol 41:523-31. 2002
    ..To assess the variability between institutions in the recurrence rate at the first follow-up cystoscopy (RR-FFC) after transurethral resection (TUR) in patients with stage Ta T1 bladder cancer...
  19. doi request reprint Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma
    Richard J Sylvester
    EORTC Headquarters, Department of Biostatistics, Brussels, Belgium Electronic address
    Eur Urol 69:231-44. 2016
    ....